All Perspectives

Tennessee lawmakers are setting a new precedent in chemical regulation, including per- and polyfluoroalkyl substances (PFAS), by signing into law an industry-backed bill that requires the use of the “best science available” when developing rules governing PFAS and other chemicals.

FDA Practice Leader and Agriculture & AgTech Industry Leader Karen Carr will participate in a panel titled “Navigating Regulatory Changes in Seed Treatment” at the 2025 CLA and RISE Regulatory Conference in Arlington, Virginia, on April 24.

Craig Gelfound, head of ArentFox Schiff’s Intellectual Property practice in Los Angeles, has once again been honored by the Daily Journal as one of the Top Intellectual Property Lawyers in California, marking 14 consecutive years of this recognition.

On April 7, the Deputy Attorney General (DAG) Todd Blanche issued a memorandum entitled “Ending Regulation By Prosecution,” detailing a significant shift in the US Department of Justice’s (DOJ) approach to digital assets.

Anthem Inc. has agreed to settle a class action lawsuit brought by participants in employee health plans administered by the insurer.

Fredrick Weber will present at the 32nd Annual NCPG Conference in San Francisco, CA, on April 22, 2025.

During the transition of the London InterBank Offered Rate (LIBOR) to the approved substitute benchmark in the United States, the Secured Overnight Financing Rate (SOFR), a basic question was raised as to whether the new benchmark and transition implementation were fair and reasonable to both the borrower, on the one hand, and the lender in loans, investors in bonds, and bank counterparties in swaps, on the other.

According to an anonymous US Environmental Protection Agency (EPA) employee, the agency is considering whether to propose a rule that would require the agency to reevaluate the health and environmental risks of certain chemicals, including per- and polyfluoroalkyl substances (PFAS).

Customs & Import Compliance Practice Leader Angela Santos was quoted on how importers are strategizing to lessen their liability under the Trump Administration’s tariffs.

As 4/20 approaches, the cannabis industry is aflame with trends and opportunities that extend beyond traditional boundaries. Recent insights reveal a dynamic shift in consumer behavior and consumption methods, offering an opportunity for companies across sectors to capitalize on the ever-evolving cannabis culture.

Ambulatory surgery centers (ASCs) have become a large and growing part of the health care industry. ASCs offer same-day surgical care, including diagnostic and preventive procedures, and their popularity has recently grown.

On April 1, the US Secretary of Commerce initiated a section 232 “national security” investigation, “to determine the effects on national security of imports of semiconductors, semiconductor manufacturing equipment (SME), and their derivative products. This includes, among other things, semiconductor substrates and bare wafers, legacy chips, leading-edge chips, microelectronics, and SME components. Derivative products include downstream products that contain semiconductors, such as those that make up the electronics supply chain.”

Headlines that Matter for Companies and Executives in Regulated Industries

Effective April 5, the United States imposed a 10% baseline tariff on imports from nearly all countries, excluding products from Canada and Mexico, and those products contained in the Harmonized Tariff Schedule of the United States Column 2 and the Annex II list attached to Executive Order 14257. In contrast, Chinese imports are subject an increased 125% reciprocal tariff rate, combined with 20% International Emergency Economic Powers Act duty rate in effect since March 4.

President Trump’s Executive Order (EO) 14187, “Protecting Children from Chemical and Surgical Mutilation,” represents a significant shift in federal policy regarding gender-affirming care (GAC) for minors.

Health Care Counsel Gayland Hethcoat will share insights into the potential future of private equity (PE) in health care in a HealthExecStore webinar on April 16, 2025.

Join Antonio Rivera for a roundtable discussion at the Battery Show South.

President Trump’s energy-focused ambitions will generate work for regulators at all levels of the government.

Gayland Hethcoat was quoted on the potential for increased data privacy litigation targeting health plans, with the Blue Shield case possibly sparking a “broader wave” of lawsuits.

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of the Inspector General (OIG), manufacturers have contested the OIG’s long-standing interpretation of the Anti-Kickback Statute (AKS).

Partner Emily Cowley Leongini was quoted on the federal court decision regarding the oversight of laboratory-developed tests by the US Food and Drug Administration.

The One Day Rest in Seven Act is an Illinois law providing employees with the right to meal breaks and one full day of rest each work week.

AI Industry Group Co-Leader Dan Jasnow will present at Artist and the Machine’s AI & Creativity Summit on April 24, 2025, in New York.

Don’t be fooled by the 90-day pause. It looks like high tariffs will be here to stay and we are in the midst of an all-out trade war with China, including a minimum 145% tariff.

Ford is seeking to stop an aftermarket restoration company from the alleged unauthorized use of the Bronco trademark and trade dress in connection with the rebuild of modern Ford Broncos. The case raises questions of whether brands are doing enough to maintain rights in iconic designs in an increasingly hot marketplace for vintage-inspired goods.